DOCSLIB.ORG

Clinical Pharmcokinetics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Pharmcokinetics INDEX INDEX A Acyclovir aminoglycosides and, 144 ABCB1, 61 antirejection agents and, 218 Abiraterone, 329 renal function and, 28, 34 Absorption Adjusted body weight, 44 of aminoglycosides, 125 Adolescence, 65, 166. See also Pediatrics of antirejection agents, 209–210 Advanced age, 295, 415. See also Geriatrics of carbamazepine, 225–226 Adverse drug reactions, 84–85 of ethosuximide, 251 AFFIRM, 246 of fosphenytoin, 335 Albiglutide, 98 geriatric differences in, 85 of lithium, 303 Alcohol use/alcoholism pediatric age-dependent differences in, 66 antidepressants and, 167 pediatric intramuscular route and, 68 by geriatric patient, 89 pediatric oral route and, 67–68 liver disease and, 167 pediatric percutaneous route and, 68 warfarin and, 416, 418 pediatric rectal route and, 68 Alendronate, 98 of phenobarbital, 324 Allopurinol of phenytoin, 334–335 antirejection agents and, 217, 219 of theophylline, 352 theophylline and, 360 of unfractionated heparin, 258–259 warfarin and, 416 of valproate, 366–367 Alprazolam, 88, 92 , 98 of vancomycin, 379 Aluminum/magnesium hydroxide, 219 of warfarin, 405 Amantadine Acarbose, 98, 417 geriatric patient and, 90, 98 ACE (angiotensin-converting enzyme) renal function and, 28, 34 inhibitors Amantadine + quinidine interaction, 25 antirejection agents and, 219 American Academy of Neurology, 195 geriatric patient and, 84, 90 lithium and, 312 American Academy of Pediatrics, 296 Acetaminophen American College of Chest Physicians, 410 carbamazepine and, 232 American Epilepsy Society, 195 geriatric patient and, 98 American Geriatrics Society, 91, 92 pediatric patient and, 72, 73 American Society for Blood and Marrow warfarin and, 416 Transplantation, 50 Acetazolamide, 88, 90, 233 American Society of Clinical Oncology, 49 Actual body weight, 41 Amikacin, 123 Acute kidney injury, 23 distribution of, 127 renal function quantification of, 24 dosage forms of, 125 vancomycin and, 393 dosing interval for, 132 Acute myocardial infarction, 295 geriatric patient and, 98 429 Unauthenticated | Downloaded 09/30/21 01:30 AM UTC 430 CLINICAL PHARMACOKINETICS pediatric patient and, 74, 75, 76 Anorexic agents, 93 pregnancy and, 146 Antacids, 218, 343 renal function and, 34 Antibiotics Amiloride, 9 antirejection agents and, 219 Aminoglutethimide, 416 drug concentration monitoring of, 3 Aminoglycoside(s), 123–153 lithium and, 312 antirejection agents and, 219 Anticoagulants, 232 body weight and, 46 Anticonvulsants dosage forms of, 124–126 antirejection agents and, 219 dosage range for, 123–124 geriatric patient and, 85 dosing strategies for, 129–135 lithium and, 312 drug concentration monitoring for, 3, 6 Antidepressants, 61, 155–171 drug–drug interactions for, 144 carbamazepine and, 232 geriatric patient and, 90 dosage forms of, 156, 158 pediatric patient and, 69, 70, 71, 72, 75–76 dosing strategies for, 160–162 pharmacodynamic monitoring of, 142–144 drug–disease state/condition and, 166–168 pharmacogenomics and, 146 geriatric patient and, 91 pharmacokinetics of, 126–128 oral dosage ranges for, 157 renal function and, 27, 32 pharmacodynamic monitoring of, 166, 167 therapeutic ranges for, 135–141 pharmacokinetics of, 156, 160 warfarin and, 416 therapeutic monitoring of, 165–166 Aminophylline, 98, 352 therapeutic range for, 162–163, 164 Amiodarone therapeutic response of, 164–165 antirejection agents and, 219 usual dosage range for, 156 geriatric patient and, 93 Antidiabetics, 85 lidocaine and, 294 Antiepileptics, 61, 173–203 phenytoin and, 343 carbamazepine and, 232 warfarin and, 416 dosage forms of, 174 Amiodipine, 99 drug concentration monitoring of, 5 Amitriptyline generic substitution of, 196 antidepressants and, 156–161, 163–164 use of newer, 195 geriatric patient and, 87, 88, 99 Antifungals, 219, 232, 233 Ammonium chloride, 25 Antihypertensives, 91 Amoxapine, 157–161, 164 Antiparkinson drugs, 91 Amoxicillin, 28, 34, 99 Antipsychotics Amphetamines, 25, 93 carbamazepine and, 232 Amphotericin, 28, 34 geriatric patient and, 91 Amphotericin B lithium and, 312 aminoglycosides and, 144 Antirejection agents, 205–222 antirejection agents and, 219 bioavailability of, 210 vancomycin and, 392 clearance values for, 212–213 Ampicillin dosage forms of, 206, 208 geriatric patient and, 99 dosage range for, 206–208 pediatric patient and, 67 drug–drug interactions of, 217–218, 219 renal function and, 28, 34 genes affecting, 220 molecular weights of, 220 Ampicillin/sulbactam, 34 pharmacodynamic monitoring of, 215–216, Amputations, 15 217 Anderson, Douglas M., 323–332 pharmacokinetics of, 209–213 Androgens, 417 protein binding of, 211 Angiotensin receptor blockers (ARBs), 312 therapeutic monitoring of, 215 therapeutic range for, 214 Unauthenticated | Downloaded 09/30/21 01:30 AM UTC INDEX 431 Apixaban ethosuzimide and, 255 geriatric patient and, 91, 99 geriatric patient and, 89, 91, 93 phenobarbital and, 329 warfarin and, 416 renal function and, 28 Bedaquiline, 329 Apremilast, 329 Beers Criteria, 91–92 Aprepitant, 219, 416 Belladonna alkaloids combination, 93 Arbekacin, 123, 124 Benazepril, 29, 34, 88, 99 Area under the curve, 386, 389–390 Benzathine penicillin G, 66 Aripiprazole Benzodiazepines geriatric patient and, 99 carbamazepine and, 232 phenobarbital and, 329 geriatric patient and, 89, 91 Ascites, 144 phenobarbital and, 329 Ascorbic acid, 416 Benzylpenicillin + probenecid interaction, 25 Asphyxia, 71–72 Bepridil, 27 Aspirin Beta-adrenergic antagonists/blockers, 294, 312 geriatric patient and, 93 , 99 Beta-agonists, 91 heparin and, 271 Beta-blockers valproate and, 372 carbamazepine and, 232 Aspirin/acetylated salicylates, 417 geriatric patient and, 89, 91 Assay issues phenobarbital and, 329 with aminoglycosides, 141 theophylline and, 360 with digoxin, 245, 246 Beta-lactams with lithium, 311 aminoglycosides and, 144 with low molecular weight heparin, 274 drug concentration monitoring of, 3 with phenobarbital, 326 pediatrics and, 69, 76 with unfractionated heparin, 266 Bicarbonate, 329 with vancomycin, 395 Bioavailability, 304, 324 Asthma, 357, 359 Biotransformation, 26 Atazanavir, 329 Birth age, 65 Atenolol, 29, 34, 99 Bisoprolol, 29, 34 Atomoxetine, 76 Bleomycin, 99 Atorvastatin, 218 Blood–brain barrier, 57, 59 ATP-binding cassette (ABC), 57, 58, 59 Boceprevir, 219, 329 Atropine, 88 Body Azathioprine composition changes of, 41–43 antirejection properties of, 205–206, mass index, 41 209–213, 216–220 Body size descriptor, 42, 43–45, 49 geriatric patient and, 99 equations for, 42 warfarin and, 416 output examples of, 44 Azithromycin, 99 Body weight, 14–15 Azole antifungals, 416 Bosentan, 416 Aztreonam, 29, 34 Bromocriptine, 219 Broth microdilution method, 385 B Bumetanide, 74 Bacitracin, 144 Buprenorphine, 329 Bainbridge, Jacquelyn L., 173–203, 223–238, Bupropion 251–256 antidepressants and, 157–161, 164–165, Barbiturates 167–168 geriatric patient and, 99 Unauthenticated | Downloaded 09/30/21 01:30 AM UTC 432 CLINICAL PHARMACOKINETICS Burns, 144 Carvedilol, 329 Buspirone, 100 Caspofungin, 219 Busulfan, 100 Cefaclor, 100 Cefamandole, 100 C Cefazolin geriatric patient and, 100 Caffeine, 351, 355 renal function and, 29, 34 geriatric patient and, 88 Cefdinir, 100 lithium and, 312, 314 Cefepime pediatric patient and, 72 geriatric patient and, 100 theophylline and, 360 renal function and, 29, 34, 36 Calcineurin inhibitors, 329 Cefixime, 100 Calcium, 86 Cefoperazone, 101 Calcium channel blockers Cefotaxime, 29 antirejection agents and, 219 geriatric patient and, 89, 91 Cefotetan, 101 lithium and, 312 Cefoxitin, 29 phenobarbital and, 329 Cefpodoxime, 101 theophylline and, 360 Cefprozil, 101 Candesartan, 100 Ceftaroline, 29, 34 Capecitabine, 416 Ceftazidime Capreomycin, 144 geriatric patient and, 101 Captopril, 100 renal function and, 29, 34 Carbamazepine, 223–238 Ceftolozane/tazobactam, 29 antiepiletic properties of, 173–174, 178–179, Ceftriaxone 182–184, 187, 189, 193 geriatric patient and, 88 dosage forms of, 224 renal function and, 34 dosage range for, 223–224 Cefuroxime dosing strategies for, 228–229 geriatric patient and, 101 drug–disease state/condition and, 232–233 IV, renal function and, 29 drug–drug interactions and, 231–232, 233 Celecoxib ethosuzimide and, 255 geriatric patient and, 101 pharmacodynamic monitoring of, 230–231 lithium and, 314 pharmacokinetics for, 225–228 warfarin and, 416 phenobarbital and, 329 Ceotaxime, 101 phenytoin and, 343 theophylline and, 360 Cephalexin, 29, 34 therapeutic monitoring of, 229–230 Cephalosporins therapeutic range for, 229 aminoglycosides and, 144 valproate and, 372, 373 renal function and, 27 warfarin and, 416 warfarin and, 416 Carbapenems, 372 Cetirizine, 29 Carbenoxolone, 88 Charcoal, 329, 360 Carbidopa, 109 Chemotherapy, 49–50 Carboplatin, 144, 417 Child/children, 65, 134–135. See also Pediatrics Cardiac disease, 167–168 Chloral hydrate, 416 Cardiac valve replacement, 419 Chlorambucil, 101 Cardiology, 60–61 Chloramphenicol Carisoprodol, 93 antirejection agents and, 219 pediatric patient and, 66 Carson, Stanley W., 301–321 Unauthenticated | Downloaded 09/30/21 01:30 AM UTC INDEX 433 phenobarbital and, 329 Citalopram phenytoin and, 343 antidepressants and, 157–161, 164–165, 167 warfarin and, 416 geriatric patient and, 102 Chlordiazepoxide, 87, 88, 89, 92, 101 Clarithromycin Chloroquine, 88 carbamazepine and, 233 Chlorpheniramine, 93, 329 geriatric patient and, 102 renal function and, 29, 34 Chlorpromazine theophylline and, 360 carbamazepine and, 231 geriatric patient and, 88, 101 Clearance phenobarbital and, 329 of aminoglycosides, 129–130 of carbamazepine, 227 Chlorpropamide, 90, 92, 102
Load more

Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column
    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
    [Show full text]
  • Synthesis and Pharmacological Evaluation of Fenamate Analogues: 1,3,4-Oxadiazol-2-Ones and 1,3,4- Oxadiazole-2-Thiones
    Scientia Pharmaceutica (Sci. Pharm.) 71,331-356 (2003) O Osterreichische Apotheker-Verlagsgesellschaft m. b.H., Wien, Printed in Austria Synthesis and Pharmacological Evaluation of Fenamate Analogues: 1,3,4-Oxadiazol-2-ones and 1,3,4- Oxadiazole-2-thiones Aida A. ~l-~zzoun~'*,Yousreya A ~aklad',Herbert ~artsch~,~afaaA. 2aghary4, Waleed M. lbrahims, Mosaad S. ~oharned~. Pharmaceutical Sciences Dept. (Pharmaceutical Chemistry goup' and Pharmacology group2), National Research Center, Tahrir St. Dokki, Giza, Egypt. 3~nstitutflir Pharmazeutische Chemie, Pharrnazie Zentrum der Universitilt Wien. 4~harmaceuticalChemistry Dept. ,' Organic Chemistry Dept. , Helwan University , Faculty of Pharmacy, Ein Helwan Cairo, Egypt. Abstract A series of fenamate pyridyl or quinolinyl analogues of 1,3,4-oxadiazol-2-ones 5a-d and 6a-r, and 1,3,4-oxadiazole-2-thiones 5e-g and 6s-v, respectively, have been synthesized and evaluated for their analgesic (hot-plate) , antiinflammatory (carrageenin induced rat's paw edema) and ulcerogenic effects as well as plasma prostaglandin E2 (PGE2) level. The highest analgesic activity was achieved with compound 5a (0.5 ,0.6 ,0.7 mrnolkg b.wt.) in respect with mefenamic acid (0.4 mmollkg b.wt.). Compounds 6h, 61 and 5g showed 93, 88 and 84% inhibition, respectively on the carrageenan-induced rat's paw edema at dose level of O.lrnrnol/kg b.wt, compared with 58% inhibition of mefenamic acid (0.2mmoll kg b.wt.). Moreover, the highest inhibitory activity on plasma PGE2 level was displayed also with 6h, 61 and 5g (71, 70,68.5% respectively, 0.lmmolkg b.wt.) compared with indomethacin (60%, 0.01 mmolkg b.wt.) as a reference drug.
    [Show full text]
  • Photopharmacologic Vision Restoration Reduces Pathological
    www.nature.com/scientificreports OPEN Photopharmacologic Vision Restoration Reduces Pathological Rhythmic Field Potentials in Blind Received: 12 March 2019 Accepted: 3 September 2019 Mouse Retina Published: xx xx xxxx Katharina Hüll 1,2, Tyler Benster3,4, Michael B. Manookin3, Dirk Trauner 2, Russell N. Van Gelder3,5 & Laura Laprell3,6 Photopharmacology has yielded compounds that have potential to restore impaired visual responses resulting from outer retinal degeneration diseases such as retinitis pigmentosa. Here we evaluate two photoswitchable azobenzene ion channel blockers, DAQ and DAA for vision restoration. DAQ exerts its efect primarily on RGCs, whereas DAA induces light-dependent spiking primarily through amacrine cell activation. Degeneration-induced local feld potentials remain a major challenge common to all vision restoration approaches. These 5–10 Hz rhythmic potentials increase the background fring rate of retinal ganglion cells (RGCs) and overlay the stimulated response, thereby reducing signal-to-noise ratio. Along with the bipolar cell-selective photoswitch DAD and second-generation RGC-targeting photoswitch PhENAQ, we investigated the efects of DAA and DAQ on rhythmic local feld potentials (LFPs) occurring in the degenerating retina. We found that photoswitches targeting neurons upstream of RGCs, DAA (amacrine cells) and DAD (bipolar cells) suppress the frequency of LFPs, while DAQ and PhENAQ (RGCs) had negligible efects on frequency or spectral power of LFPs. Taken together, these results demonstrate remarkable diversity of cell-type specifcity of photoswitchable channel blockers in the retina and suggest that specifc compounds may counter rhythmic LFPs to produce superior signal- to-noise characteristics in vision restoration. Outer retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration, afect millions of people worldwide.
    [Show full text]
  • The Comportment of Selected Pharmaceuticals in Sewage Treatment Plants
    Transactions on Ecology and the Environment vol 65, © 2003 WIT Press, www.witpress.com, ISSN 1743-3541 The comportment of selected pharmaceuticals in sewage treatment plants B. ~trenn',M. ~lara',0. ~ans~ & N. ~reuzin~er' l Institute for Water Quality and Waste Management, Vienna University of Technology, Vienna, Austria. 2 Federal Environment Agency Ltd., Vienna, Austria. Abstract The effluent of sewage treatment plants have been shown to be a significant source of pharmaceutical residuals in surface water. In order to determine and optimise the efficiency of wastewater treatment plants and derive basic knowledge on the behaviour of pharmaceuticals, different treatment steps of a municipal sewage treatment plant were investigated. Ths article deals with common pharmaceutical active compounds (PhAC) for hfferent applications which are known to occur in the effluent of wastewater treatment plants. In particular, two antibiotics (Roxithromycin, Sulfamethoxazole), two analgesicslantiphlogistics (Diclofenac, Ibuprofen), the antiepileptic Carbarnazepine, the contrast meha Iopromide, the tranquilizer Diazepam and the lipid regulator Bezafibrate were selected. The investigations have been performed on a low loaded full-scale activated sludge plant for nutrient-removal and phosphorus precipitation with a high sludge retention time (SRT) of more than 100 days. Since April 2001 grab samples of the influent and effluent were taken once every two months. Furthermore three sampling periods over 10 days were performed in October 2001 and in May and July 2002. Daily composite samples of influent and effluent were taken during these sampling periods. A typical distribution over the year was observed for the antibiotic Roxithromycin in the influent of the treatment plant. Certain substances which showed no or only part elimination in parallel performed lab scale experiments which were implemented with much lower SRT, seemed to be degraded in the full scale plant.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Drugs and Medication Guidelines Brochure
    Equine Medication Monitoring Program Drugs and Medication Guidelines January 2021 1 Introduction The California Equine Medication Monitoring Program (EMMP) is an industry funded program to ensure the integrity of public equine events and sales in California through the control of performance and disposition enhancing drugs and permitting limited therapeutic use of drugs and medications. The EMMP and the industry is dedicated and committed to promote the health, welfare and safety of the equine athlete. Owners, trainers, exhibitors, veterinarians and consignors of equines to public sales have a responsibility to be familiar with the California EMMP and the California Equine Medication Rule. California law (Food and Agricultural Code Sections 24000-24018) outlines the equine medication rule for public equine events in California. The owner, trainer and consignor have responsibility to ensure full compliance with all elements of the California Equine Medication Rule. Owners, trainers, exhibitors, veterinarians and consignors of equines to public sales must comply with both the California Equine Medication Rule and any sponsoring organization drug and medication rule for an event. The more stringent medication rule applies for the event. The California Equine Medication Rule is posted on the website: http://www.cdfa.ca.gov/ahfss/Animal_Health/emmp/ The information contained in this document provides advice regarding the California Equine Medication Rule and application of the rule to practical situations. The EMMP recognizes that situations arise where there is an indication for legitimate therapeutic treatment near the time of competition at equine events. The EMMP regulations permit the use of therapeutic medication in certain circumstances to accommodate legitimate therapy in compliance with the requirements of the rule.
    [Show full text]
  • STUDIES with NON-STEROIDAL ANTI-INFLAMMATORY DRUGS By
    STUDIES WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS by Elizabeth Ann Galbraith M.Sc., C.Biol., M.I.Biol. A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Veterinary Medicine of the University of Glasgow Department of Veterinary Pharmacology M ay 1994 ProQuest Number: 11007888 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11007888 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 4kh! TUT GLASGOW UNIVERSITY ) LIBRARY i To Ian ii TABLE OF CONTENTS Acknowledgements v Declaration vi Summary vii List of tables xi List of figures xv Abbreviations xvii Chapter 1 - General Introduction 1 Chapter 2 - General Material and Methods 29 Chapter 3 - Studies with Flunixin 3.1 Introduction 43 3.2 Experimental Objectives 44 3.3 Materials and Methods 45 3.4 Experiments with Flunixin 48 3.5 Results of Oral Experiments with Flunixin 49 3.6 Results of Intravenous Experiments with Flunixin 53 3.7 Results of Subcutaneous Experiments with Flunixin 55 3.8 Discussion 57 3.9 Tables and Figures
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Federal Register/Vol. 79, No. 97/Tuesday, May 20
    Federal Register / Vol. 79, No. 97 / Tuesday, May 20, 2014 / Rules and Regulations 28813 DEPARTMENT OF HEALTH AND animal drug applications (NADAs) and Medicine (HFV–100), Food and Drug HUMAN SERVICES 14 approved abbreviated new animal Administration, 7520 Standish Pl., drug applications (ANADAs) for oral Rockville, MD 20855, 240–276–8300, Food and Drug Administration dosage form new animal drug products [email protected]. from Pfizer, Inc., including its several 21 CFR Parts 510 and 520 subsidiaries and divisions, to Zoetis, SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 E. 42d St., New York, NY [Docket No. FDA–2014–N–0002] Inc. FDA is also amending the animal drug regulations to remove entries 10017, and its wholly owned Oral Dosage Form New Animal Drugs; describing conditions of use for new subsidiaries Alpharma, LLC; Fort Dodge Change of Sponsor animal drug products for which no Animal Health, Division of Wyeth; Fort NADA is approved, to make minor Dodge Animal Health, Division of AGENCY: Food and Drug Administration, corrections, and to reflect a current Wyeth Holdings Corp.; and its division, HHS. format. This is being done to increase Pharmacia & Upjohn Co., have informed ACTION: Final rule; technical the accuracy and readability of the FDA that they have transferred amendments. regulations. ownership of, and all rights and interest in, the 172 approved NADAs and 14 SUMMARY: The Food and Drug DATES: This rule is effective May 20, approved ANADAs in table 1 to Zoetis, Administration (FDA) is amending the 2014. Inc., 333 Portage St., Kalamazoo, MI animal drug regulations to reflect a FOR FURTHER INFORMATION CONTACT: change of sponsor for 172 approved new Steven D.
    [Show full text]
  • Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties
    0026-895X/05/6704-1053–1066$20.00 MOLECULAR PHARMACOLOGY Vol. 67, No. 4 Copyright © 2005 The American Society for Pharmacology and Experimental Therapeutics 7112/1197210 Mol Pharmacol 67:1053–1066, 2005 Printed in U.S.A. Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties Asher Peretz, Nurit Degani, Rachel Nachman, Yael Uziyel, Gilad Gibor, Doron Shabat, and Bernard Attali Department of Physiology and Pharmacology, Sackler Faculty of Medical Sciences (A.P., N.D., R.N., Y.U., G.G., B.A.) and School of Chemistry, Faculty of Exact Sciences (D.S.), Tel Aviv University, Tel Aviv, Israel Received September 10, 2004; accepted December 9, 2004 ABSTRACT The voltage-dependent M-type potassium current (M-current) hamster ovary cells. Both openers activated KCNQ2/Q3 chan- plays a major role in controlling brain excitability by stabilizing nels by causing a hyperpolarizing shift of the voltage activation the membrane potential and acting as a brake for neuronal curve (Ϫ23 and Ϫ15 mV, respectively) and by markedly slowing firing. The KCNQ2/Q3 heteromeric channel complex was iden- the deactivation kinetics. The effects of the drugs were stronger tified as the molecular correlate of the M-current. Furthermore, on KCNQ2 than on KCNQ3 channel ␣ subunits. In contrast, the KCNQ2 and KCNQ3 channel ␣ subunits are mutated in they did not enhance KCNQ1 Kϩ currents. Both openers in- families with benign familial neonatal convulsions, a neonatal creased KCNQ2/Q3 current amplitude at physiologically rele- form of epilepsy. Enhancement of KCNQ2/Q3 potassium cur- vant potentials and led to hyperpolarization of the resting mem- rents may provide an important target for antiepileptic drug brane potential.
    [Show full text]